Gene therapy for renal cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Recent molecular discoveries are transforming advanced renal cell carcinoma (RCC) treatment.
• Current targeted therapies focus on antiangiogenesis and kinase inhibitors (VEGF, PDGF, Raf, mTOR).

Purpose of the Study:

• To explore the significance of characterizing unique molecular events in RCC for gene therapy.
• To evaluate the potential of gene therapy as an adjuvant treatment for RCC.

Main Methods:

• Review of current targeted therapies and molecular understanding of RCC.
• Discussion of potential gene therapy strategies including targeting, gene transfer, and cell killing mechanisms.

Main Results:

• Gene therapy may offer true cancer cell targeting, immunomodulatory or antiangiogenic gene transfer, and novel non-apoptotic cell killing.
• Preclinical data suggests gene therapy's potential, but human trials are needed for safety and efficacy.

Conclusions:

• Gene therapy presents a promising new adjuvant modality for RCC, potentially expanding the therapeutic armamentarium.
• Future clinical trials will determine if genome-based strategies broaden the therapeutic spectrum for RCC.